Results 161 to 170 of about 20,376 (259)

Association of Antidiabetic Medication Classes With Survival Outcomes in Pulmonary Hypertension Patients With Diabetes. [PDF]

Pulm Circ
Trammell AW, Verma D, Cruse AR, Cui X, Smith MR, Hart CM.   +5 more
europepmc   +1 more source

Engineering Herbicide Cross‐Resistance in Rapeseed by Generating Stacked BnaALS Mutations via Sequential CBE and ABE8e‐SpRY Editing

Plant Biotechnology Journal, EarlyView.
Sichao Ren, Wenjing Lei, Jiaqi He, Meng Jia, Yu Liu, Jialin Fan, Yumei Wang, Li Lin, Hui Zhang, Youping Wang, Jian Wu   +10 more
wiley   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8057-8071, September 2026.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus. [PDF]

BMC Endocr Disord
Prince N, Lochnan H, Shorr R, Garon-Mailer A, Sun CJ.   +4 more
europepmc   +1 more source

Aerobic Exercise Training Increases Circulating sRAGE in Adults With Type 2 Diabetes: Associations With Sheddase Regulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8157-8171, September 2026.
ABSTRACT Objective Soluble receptor for advanced glycation end‐products (sRAGE) and soluble Toll‐like receptor 4 (sTLR4) are circulating pattern recognition receptor isoforms implicated in inflammatory regulation in type 2 diabetes mellitus (T2DM). This study examined the effects of supervised aerobic exercise training (AET) on circulating sRAGE, sTLR4,
Ryan K. Perkins, Corey E. Mazo, James Shadiow, Pallavi Varshney, Edwin R. Miranda, Victoria R. Miranda, Maggie Eisenberg, Jane E. Nakamura, Elif A. Oral, Jacob M. Haus   +9 more
wiley   +1 more source

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8367-8377, September 2026.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos, Tina Thethi, Clare J. Lee, Lisa M. Neff, Adam Stefanski, Dachuang Cao, Angel Rodriguez, Amy Bartee   +7 more
wiley   +1 more source

Medications Associated with Increased Risk of Hypoglycemia in Older Adults on Sulfonylureas: A High-Throughput Case-Crossover-Based Screening Study. [PDF]

Drug Saf
Bea S, Patorno E, Hahn G, Paik JM, Wexler DJ, Bykov K.   +5 more
europepmc   +1 more source

One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin‐Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin‐Requiring Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8208-8218, September 2026.
ABSTRACT Introduction Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear.
Ninoschka C. D'Souza, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Richard T. Liggins, Owen Chan, Michael C. Riddell   +7 more
wiley   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8172-8188, September 2026.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study. [PDF]

BMC Endocr Disord
Kiran Z, Fatima N, Baloch AA, Shaikh KUS, Hasan SM, Khan MU.   +5 more
europepmc   +1 more source